Advertisement
Research Article

Hippocampal Atrophy as a Quantitative Trait in a Genome-Wide Association Study Identifying Novel Susceptibility Genes for Alzheimer's Disease

  • Steven G. Potkin mail,

    sgpotkin@uci.edu

    Affiliation: Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California, United States of America

    X
  • Guia Guffanti,

    Affiliations: Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California, United States of America, Department of Sciences and Biomedical Technologies, University of Milan, Segrate (MI), Italy

    X
  • Anita Lakatos,

    Affiliation: Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California, United States of America

    X
  • Jessica A. Turner,

    Affiliation: Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California, United States of America

    X
  • Frithjof Kruggel,

    Affiliation: Department of Biomedical Engineering, University of California Irvine, Irvine, California, United States of America

    X
  • James H. Fallon,

    Affiliation: Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California, United States of America

    X
  • Andrew J. Saykin,

    Affiliation: Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana, United States of America

    X
  • Alessandro Orro,

    Affiliation: Istituto di Tecnologie Biomediche, Consiglio Nazionale delle Ricerche, Segrate (MI), Italy

    X
  • Sara Lupoli,

    Affiliation: Universita' Vita e Salute, Department of Neurology and Neuroscience, Milan, Italy

    X
  • Erika Salvi,

    Affiliation: Department of Sciences and Biomedical Technologies, University of Milan, Segrate (MI), Italy

    X
  • Michael Weiner,

    Affiliation: Department of Radiology, Psychiatry and Neurology, University of California San Francisco, San Francisco, California, United States of America

    X
  • Fabio Macciardi,

    Affiliations: Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California, United States of America, Department of Sciences and Biomedical Technologies, University of Milan, Segrate (MI), Italy

    X
  • for the Alzheimer's Disease Neuroimaging Initiative
  • Published: August 07, 2009
  • DOI: 10.1371/journal.pone.0006501

About the Authors

Steven G. Potkin, Guia Guffanti, Anita Lakatos, Jessica A. Turner, James H. Fallon, Fabio Macciardi
Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, California, United States of America
Guia Guffanti, Erika Salvi, Fabio Macciardi
Department of Sciences and Biomedical Technologies, University of Milan, Segrate (MI), Italy
Frithjof Kruggel
Department of Biomedical Engineering, University of California Irvine, Irvine, California, United States of America
Andrew J. Saykin
Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana, United States of America
Alessandro Orro
Istituto di Tecnologie Biomediche, Consiglio Nazionale delle Ricerche, Segrate (MI), Italy
Sara Lupoli
Universita' Vita e Salute, Department of Neurology and Neuroscience, Milan, Italy
Michael Weiner
Department of Radiology, Psychiatry and Neurology, University of California San Francisco, San Francisco, California, United States of America

Corresponding Author

Email: sgpotkin@uci.edu

Competing Interests

Dr. Potkin has read the journal's policy and declares the following competing interest: Dr. Potkin has received funding for this project from NIAAA and NIBIB, Vanda Pharmaceuticals and an anonymous foundation. Dr. Potkin has received grant support or has been a consultant to several companies that have contributed to the NIH Foundation that has provided some financial support for the ADNI study including Pfizer Inc., Wyeth Research, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co. Inc., AstraZeneca AB, Novartis Pharmaceuticals Corporation, Alzheimer's Association, Elan Corporation plc, and Forest Laboratories.

Author Contributions

Conceived and designed the experiments: SGP AS MW. Analyzed the data: GG AL JT FK JF SL ES FM. Contributed reagents/materials/analysis tools: AO. Wrote the paper: SGP GG AL JT FK JF FM.